Stockreport

Insight Molecular Diagnostics outlines $1B transplant testing market expansion as company nears FDA submission [Seeking Alpha]

Insight Molecular Diagnostics Inc.  (IMDX) 
PDF CEO Joshua Riggs highlighted that Insight Molecular Diagnostics is nearing a transformative milestone, stating, "In 2026, with the expected FDA authorization of GraftAs [Read more]